Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma

  • Technology appraisal guidance
  • TA169
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

September 2025: We updated section 3.3 to reflect the updated list price of sunitinib and the removal of the patient access scheme.

February 2014: We updated the implementation section to clarify that sunitinib is recommended as an option for treating advanced and/or metastatic renal cell carcinoma.

ISBN: 978-1-4731-5678-4